Among the 13 new drug marketing applications that the European Medicines Agency has most recently accepted for review are two products that could become the first approved treatments for children with progressive familial intrahepatic cholestasis, a life-threatening disorder.
The European Medicines Agency has added 13 new products to its list of investigational drugs that are under review for...